Premium
Magnetic resonance spectroscopy in prostate disease: Diagnostic possibilities and future developments
Author(s) -
Narayan Perinchery,
Kurhanewicz John
Publication year - 1992
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990210507
Subject(s) - prostate , prostate cancer , magnetic resonance imaging , phosphomonoesters , medicine , phosphocreatine , in vivo magnetic resonance spectroscopy , pathology , cancer , nuclear magnetic resonance , nuclear medicine , radiology , energy metabolism , physics
Magnetic resonance spectroscopy (MRS) is a relatively new technique for studying membrane and intracellular metabolic events occurring in cancer. A series of transrectal probes were used for performing MRS and subsequently for integrated MRS/magnetic resonance imaging (MRI) of the prostate. Studies using transrectal 31 P/ 1 H MRS showed that it can characterize metabolic differences between normal and malignant prostates. Specifically, malignant prostates are characterized by low levels of phosphocreatine and citrate and high levels of phosphomonoesters relative to normal glands. These findings were verified in biochemical studies of prostate biopsies. The images obtained by transrectal coil techniques were superior to images obtained by the conventional body coil technique. In the future, the integration of 1 H imaging and multi‐volume localization techniques (spectroscopic imaging) will allow the acquisition of metabolic maps of the prostate which may eventually be useful in diagnosis and in management of patients with prostate cancer.